by Market Overview:
Bacterial sialadenitis is a bacterial infection of the salivary glands. The condition causes swelling and pain of the major and minor salivary glands. Antibiotics are generally prescribed to treat bacterial sialadenitis by targeting the infecting bacteria.
Market key trends:
One of the major trends in the bacterial sialadenitis market is the rise in research activities for developing novel therapeutics. Salivary gland disorders have significant impact on quality of life. However, treatment options for bacterial sialadenitis are limited. Hence, key companies are increasing their research funding towards development of new drug molecules with improved efficacy and safety profile. For instance, in 2019, researchers from University of Sussex evaluated gallium as an antimicrobial agent for treatment of bacterial infections including bacterial sialadenitis. Gallium showed potential in vitro activity against various bacterial strains.
The global Bacterial Sialadenitis Market Share is estimated to be valued at US$ 1.90 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The main key trend in the bacterial sialadenitis market is the rising prevalence of infectious and chronic diseases impacting the salivary glands. Bacterial infection in the salivary glands is commonly caused by Staphylococcus aureus and Streptococcus pneumoniae bacteria. Persistent swelling and inflammation of the salivary glands due to infection can lead to complications and cause pain and tenderness around the affected area. The rising cases of chronic diseases such as Sjogren’s syndrome that increases the risk of bacterial sialadenitis is a major factor promoting the growth of this market.
SWOT Analysis
Strength: Growing awareness about complications of untreated bacterial infections. Wide availability of effective antibiotic drugs for treatment.
Weakness: Expensive treatment cost of long-term antibiotic therapy in severe cases. Lack of standardized treatment guidelines.
Opportunity: Increased funding for research on developing novel treatment strategies. Untapped growth potential in developing markets.
Threats: Threat of antibiotic resistance due to overuse or misuse of drugs. Risk of infection recurrence after initial treatment.
Key Takeaways
The global bacterial sialadenitis market is expected to witness high growth, exhibiting CAGR of 5.6% over the forecast period, due to increasing prevalence of chronic diseases impacting the salivary glands.
The market size for 2023 is US$ 1.90 Bn. North America is expected to dominate the global market during the forecast period owing to developed healthcare infrastructure and presence of major players in the region.
Regional analysis
Europe is expected to show lucrative growth in the bacterial sialadenitis market during 2023-2030 due to rising research on oral health and increasing cases of primary Sjogren’s syndrome reported from countries like Germany and Italy.
Key players operating in the bacterial sialadenitis market are Pfizer Inc.,Merck & Co., Inc., GlaxoSmithKline plc,Novartis AG,Sanofi S.A., Johnson & Johnson,Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc,Bayer AG, Bristol-Myers Squibb Company,Roche Holding AG,Teva Pharmaceutical Industries Ltd.,Mylan N.V.,Allergan plc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
